INOVIQ Ltd (ASX:IIQ) is a biotechnology company pioneering next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours.
31/10/2024 08:24:00
Lodging this quarterly update, Chairman David Williams said: “Progress continued across our commercial, development and corporate activities. Promega is gaining new EXO-NET customers and there…
Market Reports /
by Lauren Hayes -
2 years ago
13 Dec 2022 - The local market has bounced back this morning, following a positive lead from Wall Street overnight, with investors looking ahead to the highly anticipated Federal R…
Market Reports /
by Peter Milios -
2 years ago
28 Nov 2022 - Amidst the ongoing tensions arising from the continuation of China’s lockdowns from their recent COVID surge, oil has fallen to its lowest point since December 2021, …
Market Reports /
by Peter Milios -
2 years ago
28 Nov 2022 - China’s persistent lockdowns have caused commodity prices and futures to fall.
Market Reports /
by Peter Milios -
2 years ago
25 Nov 2022 - The S&P/ASX 200 is 0.29 per cent or 20.70 points higher at 7262.50 at noon. It is a bleak end to the week for the lithium sector, with many of its players down substa…
Market Reports /
by Lauren Hayes -
2 years ago
28 Oct 2022 - Disappointing earnings from major US tech companies, including Meta, Apple and Amazon, has caused the Information Technology sector on the ASX to fall by 2.17 per cen…
Market Reports /
by Peter Milios -
2 years ago
13 Oct 2022 - It was a tumultuous day of trading. There was a peak of near 1 per cent high at lunchtime. However, pessimism surrounded the upcoming US CPI data. At the closing bell…
Market Reports /
by Lauren Hayes -
2 years ago
13 Oct 2022 - Financials have been keeping the ASX in positive territory in today’s session, following improved sentiment for financial stocks after the Bank of Queensland (ASX:BOQ…
Market Reports /
by Lauren Hayes -
2 years ago
28 Sep 2022 - It was choppy trading on the ASX today with the S&P/ASX 200 commencing the session in positive territory, before slipping into the red for afternoon trading but clawi…
Market Reports /
by Lauren Hayes -
2 years ago
28 Sep 2022 - The ASX gave up modest gains in this morning’s trade to dip into the red at lunchtime trading. China's rapid build-up of clean energy is claiming more copper, support…
Interviews /
by Tim McGowen -
2 years ago
29 Jul 2022 - INOVIQ Limited (ASX:IIQ) CEO Dr Leearne Hinch discusses recent key announcements, including the appointment of a US sales team, the securing of a US patent, quarterly…
Market Reports /
by Paul Sanger -
2 years ago
26 Jul 2022 - The S&P/ASX 200 closed marginally higher on Tuesday in a reasonably quiet trading session as investors prepare themselves for the busiest week of corporate earnings i…
Market Reports /
by Paul Sanger -
2 years ago
26 Jul 2022 - The S&P/ASX 200 traded flat by midday in Sydney as traders prepared themselves for the busiest week of corporate earnings in the US, Thursday’s Federal Reserve meetin…
Market Reports /
by Lauren Evans -
2 years ago
01 Jul 2022 - The Australian sharemarket faded into the close, weighed down by US equity futures in a risk-off afternoon. The greenback rose against the Australian dollar, which h…
Company Presentations /
by -
3 years ago
04 Nov 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch provides an update on its multi-product pipeline diagnostic technologies across a range of different cancer…
Interviews /
by Lauren Evans -
3 years ago
29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
